Results 131 to 140 of about 12,023 (194)

PK/PD-guided ceftazidime-avibactam dosing for multidrug-resistant <i>Pseudomonas aeruginosa</i> infection in a preterm infant with chylothorax and ascites: a case report. [PDF]

Front Pharmacol
Yuan W, Zhao X, Liu X, Tao X, Zeng L.
europepmc   +1 more source

Disease severity modifies the ceftazidime-avibactam exposure-response relationship in critically ill patients: a retrospective study. [PDF]

Front Pharmacol
Qian S, Xu D, Xu Y, Qi H, Liang P.
europepmc   +1 more source

Contemporary multicentre analysis of carbapenemases distribution among clinical carbapenem-resistant Enterobacterales in Lebanon. [PDF]

JAC Antimicrob Resist
Tannous J, Saliba R, Mghames A, Tokajian S, Attieh R, Jisr T, Barhoun J, Diab MK, Shakra DA, Mokhbat J, Al Souheil A, Zorkot W, Jaffal F, Salman H, Husni R, Rahban H, Khoury E, Mohsen Z, Abboud E, Youssef M, Karayakoupoglo G, Fawaz I, Houmani M, Abdallah D, Moghnieh R.   +24 more
europepmc   +1 more source

A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol. [PDF]

mBio
Kawai A, McElheny CL, Shields RK, Arias CA, Paterson DL, Patel R, Bonomo RA, Fowler VG, van Duin D, Doi Y.   +9 more
europepmc   +1 more source

<i>In vitro</i> activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan. [PDF]

JAC Antimicrob Resist
Yanagihara K, Tateda K, Doi Y, Takahashi S, Ohge H, Itahashi K, Okade H, Mikamo H.   +7 more
europepmc   +1 more source

Comment on "evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation". [PDF]

Int J Clin Pharm
Aljumaa SA, Al Musawa M, El Lababidi R, Abidi E, Ghazi I, El Nekidy WS.   +5 more
europepmc   +1 more source

Likelihood of aggressive PK/PD target attainment of continuous-infusion beta-lactams during the first week of treatment of febrile neutropenia: findings from a 1-year prospective, monocentric study in onco-haematological patients. [PDF]

J Antimicrob Chemother
Cojutti PG, Toschi A, Pasquini Z, Paolini S, Maffini E, Bonifazi F, Zinzani PL, Giannella M, Viale P, Pea F.   +9 more
europepmc   +1 more source

Accurate and Sensitive UHPLC-Tandem Mass Spectrometry Sequential Methods for Therapeutic Drug Monitoring of Aztreonam/Avibactam in Human Plasma. [PDF]

Pharmaceutics
Trozzi I, Giorgi B, De Paola R, Gatti M, Pea F.   +4 more
europepmc   +1 more source

The <i>in vitro</i> activity of aztreonam-avibactam and cefiderocol against globally collected clinical metallo-β-lactamase- and/or serine-carbapenemase-positive Enterobacterales isolates and the utility of commonly used <i>in vitro</i> diagnostic kits. [PDF]

Microbiol Spectr
Estabrook M, Streit C, Townsend A, Stone G, Kamat S, Sahm D.   +5 more
europepmc   +1 more source

Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam. [PDF]

BMC Genom Data
Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +1 more source